Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis – a clinical update on efficacy and safety

Author： Deal Chad L Draper Michael W

Publisher： Future Medicine

ISSN： 1745-5057

Source： Women's Health, Vol.2, Iss.2, 2006-03, pp. : 199-210

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis

By Palacios Santiago

Current Medical Research and Opinion, Vol. 26, Iss. 7, 2010-07 ,pp. : 1553-1563

Informa Healthcare

Access to resources Recommend Favorite

Bazedoxifene: a selective estrogen-receptor modulator

By Mitwally Mohamed FM

Women's Health, Vol. 4, Iss. 4, 2008-07 ,pp. : 319-326

Future Medicine

Access to resources Recommend Favorite

Raloxifene: a selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women

By Vogel Victor G

Women's Health, Vol. 3, Iss. 2, 2007-03 ,pp. : 139-153

Future Medicine

Access to resources Recommend Favorite

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis

By Iwamoto Jun Takeda Tsuyoshi Sato Yoshihiro

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 919-928

Informa Healthcare

Access to resources Recommend Favorite

Long-term raloxifene for postmenopausal osteoporosis

By Recker Robert R. Mitlak Bruce H. Ni Xiao Krege John H.

Current Medical Research and Opinion, Vol. 27, Iss. 9, 2011-09 ,pp. : 1755-1761

Informa Healthcare

Access to resources Recommend Favorite